NO160211B - Analogifremgangsmaate til fremstilling av nye terapeutisk virksomme cefemderivater. - Google Patents

Analogifremgangsmaate til fremstilling av nye terapeutisk virksomme cefemderivater. Download PDF

Info

Publication number
NO160211B
NO160211B NO781130A NO781130A NO160211B NO 160211 B NO160211 B NO 160211B NO 781130 A NO781130 A NO 781130A NO 781130 A NO781130 A NO 781130A NO 160211 B NO160211 B NO 160211B
Authority
NO
Norway
Prior art keywords
magnets
magnet
liquid
passage
poles
Prior art date
Application number
NO781130A
Other languages
English (en)
Other versions
NO781130L (no
NO160211C (no
Inventor
Walter Duerckheimer
Dieter Bormann
Eberhard Ehlers
Elmar Schrinner
Rene Heymes
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO781130L publication Critical patent/NO781130L/no
Publication of NO160211B publication Critical patent/NO160211B/no
Publication of NO160211C publication Critical patent/NO160211C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/50Nitrogen atoms bound to hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D463/00Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/10Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D463/14Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms directly attached in position 7
    • C07D463/16Nitrogen atoms
    • C07D463/18Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D463/20Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D463/22Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D505/00Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Description

Anordning for behandling av væske, og magnet for en slik anordning.
Denne oppfinnelse angår en anordning
for behandling av væsker ved hjelp av
kraftlinjene i et magnetisk felt forsynt
med i det minste ett gjennomløp for den
væske som skal behandles, og organer for
over en del av nevnte gjennomløp å frembringe et magnetisk felt hvis kraftlinjer
står i hovedsaken vinkelrett på gjennom-løpets lengderetning.
Slike anordninger nyttes for behandling av væsker som forårsaker kalkholdige
skjelldannelser, likesom for generelt å redusere slike væskers tærende virkning.
Enn videre er den magnetiske kondisjonering av væsker allerede kjent, særlig
i henhold til de fremgangsmåter som ut-føres ved hjelp av de anordninger som tidligere er tilveiebragt av oppfinneren og
bl. a. ved hjelp av de anordninger som om-handles i de belgiske patenter nr. 460 560,
486 497 og 492 580.
Ved de hittil kjente anordninger frem-bringes imidlertid de magnetiske felt enten
av spoler som forsynes med veksel- eller
likestrøm, eller av permanentmagneter med
en mere eller mindre vanlig utførelse, f. eks.
rette, sylindriske eller halvsylindriske magneter.
Den foreliggende oppfinnelse angår
derimot i første rekke en anordning som
bygger på en fullstendig ny idé, som med-fører arbeids- og materialbesparelser, sam-tidig som den sikrer bedre resultater enn
tidligere.
For oppnåelse av disse formål består
de nevnte organer som frembringer det
magnetiske felt av to magneter som strekker seg parallelt med hverandre i lengderetningen av gjennomløpet, som på midten er forsynt med to mot hverandre vendte fremspring som danner poler med motsatt polaritet, idet det i begge ender av magnetene fins andre poler, som for en og samme magnet har motsatt polaritet av denne magnets midtre fremspringende pol.
Ved en foretrukket utføringsform for oppfinnelsen kan magnetene være gjensidig forbundet ved knaster som danner endepolene.
Oppfinnelsen omfatter ikke bare den ovenfor angitte anordning, men innbefat-ter også hver enkelt magnet konstruert for en slik anordning.
Andre detaljer og trekk ved oppfinnelsen vil fremgå av den etterfølgende beskri-velse av et utføringseksempel på en anordning for behandling av en væske, og en magnet for en slik anordning, under hen-visning til tegningen. Fig. 1 er et vertikalt lengdesnitt av et par magneter inngående i anordningen for behandling av en væske i henhold til oppfinnelsen; Fig. 2 viser den ene (undre) magnet i
fig. 1 i grunnriss;
Fig. 3 er et snitt gjennom en rekke samordnede magnetpar ifølge de foregå-ende figurer, med magnetene plassert på en fordelaktig måte i forhold til hverandre i anordningen for behandling av en væske i henhold til oppfinnelsen; snittet er tatt etter linjen III-III i fig. 1.
I de forskjellige figurer betegner like henvisningstall tilsvarende elementer.
Anordningen for behandling av væsker ved hjelp av kraftlinjene i magnetiske felt, for å redusere den tærende virkning av slike væsker og for å "forhindre nevnte væsker fra å forårsake kalkholdige skjelldannelser, kan bestå av et par permanentmagneter av den type som er vist i fig. 1. Som forklart nedenfor kan en slik anordning for væskebehandling omfatte mange slike magnetpar, så som vist i fig. 3.
Hver av magnetene i det i fig. 1 viste magnetpar består av et magnetisk legeme som strekker seg i hovedsaken i lengderetningen og parallelt med væskestrømmen.'
Den øvre magnet er betegnet med hen-visningstallet 1 og den undre magnet med 2. Hver magnet har en pol med samme polaritet i begge ender, og er midt mellom endepolene utformet med et fremspringende parti 5 resp. 6, som har motsatt polaritet av endepolene for en og samme magnet. Den undre magnet 2 har en nordpol i hver ende og en sydpol på midten som dannes av fremspringet 5. Den øvre magnet 1 har en sydpol i hver ende og en nordpol på midten dannet av fremspringet 6. Endepolene av magnetene 1 og 2 har motsatt polaritet, så at legemene 1 og 2 trekkes mot hverandre av den magnetiske tiltreknings-kraft, som ikke bare virker i endene av magnetene, men også i området for fremspringene 5, 6, ettersom hver ende av en magnet kommer i kontakt med en ende av den annen magnet som danner en pol med motsatt polaritet, og fremspringet på den ene magnet er vendt mot et fremspring på den annen magnet som danner en pol med motsatt polaritet.
Endene av magnetene er utformet som knaster 3 og 4, som berører og tiltrekker hverandre langs plane flater. Høyden på knastene 3 og 4 er større enn høyden på fremspringene 5 og 6, på en slik måte at det med magnetene i sammensatt tilstand (fig. 1) med knastene 3 og 4 i kontakt, gjenstår et fritt gjennomløp mellom fremspringene 5, 6. Avstanden mellom fremspringene 5, 6 er imidlertid vesentlig mindre enn avstanden mellom magnetene 1, 2 på de øvrige steder, selvsagt med unntakelse av området for kontaktflatene av knastene 3 og 4. Mellom parene av knaster 3 resp. 4 er det imidlertid en betydelig fri gjennomgangsåpning for væske. Kraftlinjene i de magnetiske felt befinner seg selv-følgelig nesten utelukkende inne i magnetene, med unntakelse av den korte vei kraftlinjene må følge mellom fremspringene 5, 6. Luftgapet på dette sted er således meget smalt, på en slik måte at den magnetiske fluks kan være sterkt konsentrert i dette luftgap. Det magnetiske felt utnyttes således nesten 100 pst., hvilket betyr en gevinst på ca. 30 pst. i magnetisk mate-riale i forhold til de vanlige utførelser.
I området for dette luftgap, dvs. mellom fremspringene 5 og 6, står kraftlinjene i det magnetiske felt antydet med 7 i hovedsaken vinkelrett på «væsketrådene» som er parallelle med pilene 8 som angir strømningsretningen for væsken.
Det skal bemerkes at det i fig. 1 viste magnetpar eller en rekke identiske magnetpar som vist i fig. 3 er anbragt inne i et rør som således omslutter magnetene som er anbragt side ved side i kontakt med hverandre. Dette rør tjener bare til å holde de enkelte magneter på deres resp. plass og har således ingen betydning med hensyn til styrken av de magnetiske felt. Røret er ikke vist på tegningsfigurene. Det består fortrinnsvis av ikke-ferromagnetisk mate-riale.
Væsken som passerer gjennom anordningen i retning av pilene 8 finner et gjen-nomløp med tilstrekkelig stort tverrsnitt mellom knastene 3, 4, hvilket gjennomløp forblir stort nok mellom magnetene 1, 2 også bakenfor knastene, men har et meget mere begrenset område mellom fremspringene 5 og 6. Ettersom magnetparet er sym-metrisk i forhold til et tverrsnitts- (parallelt med snittlinjen III-III) plan gjennom fremspringene 5, 6, får væskegjennomløpet bakenfor området for fremspringene 5, 6 igjen et meget større areal, på en slik måte at den fullstendige kanal mellom de to magneter 1,2 får form av en venturi, der den minste avstand forefinnes i området for luftgapet, hvor magnetfeltet er sterkest, d.v.s. mellom fremspringene 5, 6. Væskens strømningshastighet er således størst i luftgapet, hvilket er overordentlig fordelaktig, ettersom effektiviteten av den magnetiske kondisjonering på den ene side er avhengig av feltstyrken og på den annen side av væskens strømningshastighet. Det lille strømningsareal i området for luftgapet resulterer i en større hastighet og den lille avstand mellom de to fremspring som danner motsatte poler bevirker stor konsentra-sjon av den magnetiske fluks. Venturifor-men minsker den hydrauliske motstand.
På grunn av den meget store strøm-ningshastighet, medtas urenhetene, f. eks. jernoksydene, av væsken og de kastes således for en stor del ut av apparatet, på en slik måte at det er mindre fare for tilstop-ping av anordningen innenfor det magnetiske gap.
Alle disse fordelaktige trekk tillater bruk av vanlige magneter for kondisjonering av forskjellige væsker, mens det tidligere av tekniske årsaker var nødvendig å velge magnetene med hensyn til det nød-vendige magnetiske felt, som på sin side måtte velges ut fra den elektrolytiske for-mel for den væske som skulle behandles.
Fig. 3 viser hvordan det er mulig å bygge opp et batteri av magnetpar, hvor hvert magnetpar tjener samme formål som beskrevet ovenfor. Det fremgår mere tyde-lig av fig. 3. at magnetene, som er plassert rygg mot rygg og som tilhører to forskjellige par, f. eks. magnetene 9 og 10, har like poler i endene og således også på midten. Magnentene 9 og 10 har således nordpoler i endene og en sydpol på midten. Med mag-netparene således anordnet rygg mot rygg med lik polaritet, rettes den magnetiske fluks sterkere mot luftgapene, ettersom den ikke har anledning til å unnslippe andre steder, og den tiltrekkes i luftgapet.
Selvom de viste magneter har rektan-gulært tverrsnitt, kan magneter ifølge oppfinnelsen istedenfor ha en hvilken som helst annen geometrisk form. Formen må imidlertid fortrinnsvis tillate en perfekt sammenstilling av magnetene som beskrevet i forbindelse med fig. 3, men dette krav kan tilsidesettes når det er tale om magneter anordnet i individuelle par inne i et rør.

Claims (2)

1. Anordning for behandling av en væske ved hjelp av kraftlinjene i et magnetisk felt med i det minste et gjennomløp for den væske som skal behandles og organer for over en del av nevnte gjennomløp å frembringe et magnetisk felt hvis kraftlinjer står i hovedsaken vinkelrett på lengderetningen av gjennomløpet, karakterisert ved at nevnte organer som frembringer det magnetiske felt består av to magneter (1, 2) som strekker seg parallelt med hverandre i lengderetningen av gjennomløpet, idet de på midten er forsynt med fremspring (5, 6) som er vendt mot hverandre og danner poler med motsatt polaritet, og at det i begge ender av magnetene (1, 2) forefinnes andre poler (3, 4) som for en og samme magnet har motsatt polaritet i forhold til det tilhør-ende fremspring.
2. Anordning som angitt i påstand 1, karakterisert ved at magnetene sammenholdes gjensidig gjennom knaster (3, 4) dannende endepolene.
NO781130A 1977-04-02 1978-03-31 Analogifremgangsmaate til fremstilling av nye terapeutisk virksomme cefemderivater. NO160211C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19772714880 DE2714880A1 (de) 1977-04-02 1977-04-02 Cephemderivate und verfahren zu ihrer herstellung
DE19772716707 DE2716707A1 (de) 1977-04-02 1977-04-15 Cephemderivate und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
NO781130L NO781130L (no) 1978-10-03
NO160211B true NO160211B (no) 1988-12-12
NO160211C NO160211C (no) 1989-03-22

Family

ID=25771827

Family Applications (1)

Application Number Title Priority Date Filing Date
NO781130A NO160211C (no) 1977-04-02 1978-03-31 Analogifremgangsmaate til fremstilling av nye terapeutisk virksomme cefemderivater.

Country Status (28)

Country Link
US (4) US4758556A (no)
JP (2) JPS5858354B2 (no)
AT (1) AT367425B (no)
AU (1) AU528277B2 (no)
BE (1) BE865632A (no)
CA (1) CA1259606A (no)
CH (1) CH638810A5 (no)
CS (1) CS208747B2 (no)
DD (1) DD137231A5 (no)
DE (2) DE2714880A1 (no)
DK (1) DK165060C (no)
ES (2) ES468475A1 (no)
FI (1) FI70221C (no)
FR (3) FR2385722B1 (no)
GB (1) GB1604971A (no)
GR (1) GR73632B (no)
HK (1) HK39083A (no)
IE (1) IE47211B1 (no)
IL (1) IL54407A (no)
IT (1) IT1093750B (no)
LU (1) LU79350A1 (no)
NL (1) NL7803486A (no)
NO (1) NO160211C (no)
NZ (1) NZ186842A (no)
OA (1) OA05928A (no)
PT (1) PT67856B (no)
SE (2) SE448378B (no)
YU (1) YU41827B (no)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493833A (en) * 1976-04-12 1985-01-15 Fujisawa Pharmaceutical Co., Ltd. Syn-isomer of 3,7-disubstituted-3-cephem-4-carboxylic acid compounds
US4304770A (en) 1976-04-12 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. Syn-isomer of 3,7-disubstituted-3-cephem-4-carboxylic acid compounds and processes for the preparation thereof
BE878514A (fr) * 1978-09-04 1980-02-29 Fujisawa Pharmaceutical Co Procede de preparation de composes d'acide 3-cephem-4-carboxylique a disubstitution en positions 3 et 7, nouveaux produits ainsi obtenus et leur utilisation pour leur activite antibacterienne
BE878433A (fr) * 1978-08-31 1980-02-25 Fujisawa Pharmaceutical Co Procede de preparation de derives d'acide 3-cephem-4-carboxylique 3,7-disubstitue, nouveaux produits ainsi obtenus et leur utilisation pour leur activite antibacterienne
US4409217A (en) * 1977-03-14 1983-10-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
PH17188A (en) 1977-03-14 1984-06-14 Fujisawa Pharmaceutical Co New cephem and cepham compounds and their pharmaceutical compositions and method of use
US4427674A (en) 1977-03-14 1984-01-24 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
FR2399418A1 (fr) * 1977-03-14 1979-03-02 Fujisawa Pharmaceutical Co Procede de preparation d'acides iminoacetiques et nouveaux produits ainsi obtenus, utilises pour la synthese d'acides cepham- ou cephem-carboxyliques
US5089490A (en) * 1977-04-02 1992-02-18 Hoechst Aktiengesellschaft Cephem derivatives
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
JPS5444695A (en) * 1977-09-13 1979-04-09 Fujisawa Pharmaceut Co Ltd 3,7-disubstituted-3-cephem-4-carboxylic acid and its salt and their preparation
FR2410655A1 (fr) * 1977-12-05 1979-06-29 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-substitue 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
FR2387235A1 (fr) 1978-01-23 1978-11-10 Fujisawa Pharmaceutical Co Procede de preparation de composes d'acide 3,7-disubstitue-3-cephem-4-carboxylique et nouveaux produits ainsi obtenus, ayant une forte activite antibacterienne
SE7902598L (sv) * 1978-03-25 1979-10-04 Kyowa Hakko Kogyo Kk Cephalosporinanaloger
JPS5936914B2 (ja) * 1978-06-24 1984-09-06 協和醗酵工業株式会社 セフアロスポリン類縁体
NO790956L (no) * 1978-03-25 1979-09-26 Kyowa Hakko Kogyo Kk Analogifremgangsmaate til fremstilling av cefalosporinanaloge eller farmasoeytisk akseptable salter derav
FR2432521A1 (fr) * 1978-03-31 1980-02-29 Roussel Uclaf Nouvelles oximes o-substituees derivees de l'acide 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
SE448379B (sv) * 1978-03-31 1987-02-16 Roussel Uclaf O-substituerade oximderivat av 7-amino-tiazolyl-acetamidocefalosporansyra
US4374834A (en) * 1978-04-07 1983-02-22 Roussel Uclaf Novel compounds
FR2421907A1 (fr) * 1978-04-07 1979-11-02 Roussel Uclaf Nouvelles cephalosporines derivees de l'acide 7-/2-(2-amino 4-thiazolyl)2-(carboxymethoxyimino/acetamido 3-substitue cephalosporanique, leur procede de preparation et leur application comme medicaments
AR231986A1 (es) * 1978-05-26 1985-04-30 Glaxo Group Ltd Procedimiento para preparar antibioticos de cefalosporina
AR229883A1 (es) * 1978-05-26 1983-12-30 Glaxo Group Ltd Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato
DE2967356D1 (en) * 1978-07-17 1985-02-28 Fujisawa Pharmaceutical Co Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
US4372952A (en) 1978-07-31 1983-02-08 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4284631A (en) * 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
FR2453161A1 (fr) * 1978-08-31 1980-10-31 Fujisawa Pharmaceutical Co Procede de preparation de derives d'acide thiazolylacetique et nouveaux produits ainsi obtenus
US4341775A (en) * 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
BE878637A (fr) * 1978-09-11 1980-03-06 Fujisawa Pharmaceutical Co Procede de preparation de composes d'acide 3-cephem-4-carboxylique 3,7-disubstitue et de leurs sels pharmaceutiquement acceptables, nouveaux produits ainsi obtenus et leur utilisation pour leurs activites antimicrobiennes
DE2945248A1 (de) * 1978-11-13 1980-05-22 Fujisawa Pharmaceutical Co Cephem-verbindungen, verfahren zu ihrer herstellung und sie enthaltende antibakterielle pharmazeutische mittel
JPS5585594A (en) * 1978-11-13 1980-06-27 Fujisawa Pharmaceut Co Ltd Cephem compound and their preparation
SE7909501L (sv) * 1978-11-17 1980-05-18 Glaxo Group Ltd Cefalosporin-antibiotika
JPS5579393A (en) * 1978-12-11 1980-06-14 Takeda Chem Ind Ltd Cephalosporin derivative and its preparation
JPS6058920B2 (ja) * 1978-12-26 1985-12-23 協和醗酵工業株式会社 セフアロスポリン類縁体
FR2448543A1 (fr) 1979-02-09 1980-09-05 Roussel Uclaf Nouvelles oximes o-substituees par un radical comportant un ammonium quaternaire et derivees de l'acide 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
JPS55108877A (en) * 1979-02-10 1980-08-21 Kyowa Hakko Kogyo Co Ltd Optically active cephalosporin analog
JPS5616491A (en) * 1979-07-19 1981-02-17 Kyowa Hakko Kogyo Co Ltd Cephalosporin analog
NO155547C (no) * 1979-02-10 1987-04-15 Kyowa Hakko Kogyo Kk Optisk aktive cefalosporin-analoge og salter derav samt fremgangsmaate for deres fremstilling.
JPS5671092A (en) * 1979-11-14 1981-06-13 Kyowa Hakko Kogyo Co Ltd Optical active cephalosporin analogous derivative
NO155548C (no) * 1979-02-10 1987-04-15 Kyowa Hakko Kogyo Kk Fremgangsmaate til fremstilling av optisk aktive cefalosporin-analoger.
NZ193212A (en) * 1979-03-22 1982-12-07 Glaxo Group Ltd Cephalosporin antibiotics and pharmaceutical compsitions
US4339449A (en) 1979-03-27 1982-07-13 Fujisawa Pharmaceutical Company, Limited Analogous compounds of cephalosporins, and pharmaceutical composition comprising the same
US4331666A (en) * 1979-05-11 1982-05-25 Farmitalia Carlo Erba S.P.A. 3-[(8-Carboxy-6-tetrazolo[1,5-b]pyridazinyl)-thiomethyl]-7-[2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido]-3-cephem-4-carboxylic acid
FR2461713A1 (fr) * 1979-07-19 1981-02-06 Roussel Uclaf Nouvelles alcoyloximes substituees derivees de l'acide 7-(2-amino 4-thiazolyl) acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
EP0025199B1 (en) 1979-09-03 1984-10-31 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds, processes for their preparation and pharmaceutical compositions containing them
US4271157A (en) 1980-02-28 1981-06-02 E. R. Squibb & Sons, Inc. Imidazole derivatives of 7-[(2-amino-4-thiazolyl)-oximino] cephalosporins
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4409214A (en) * 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4409215A (en) * 1979-11-19 1983-10-11 Fujisawa Pharmaceutical Co., Ltd. 7-Acylamino-3-substituted cephalosporanic acid derivatives and processes for the preparation thereof
US4443443A (en) * 1979-12-17 1984-04-17 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4405617A (en) * 1980-02-11 1983-09-20 Fujisawa Pharmaceutical Co., Ltd. 3-(Propynyltetrazol)thiomethyl-3-cephems
FR2476087A1 (fr) * 1980-02-18 1981-08-21 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkyl-thiomethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
EP0104671B1 (fr) * 1980-02-18 1990-05-23 Roussel-Uclaf Nouvelles oximes dérivées de l'acide 3-alkyloxy ou 3-alkylthiométhyl-7 amino thiazolylacétamido céphalosporaniques, leur préparation, leur application comme médicaments et les compositions les renfermant
JPS56131591A (en) * 1980-02-20 1981-10-15 Fujisawa Pharmaceut Co Ltd 3,7-disubstituted-3-cephem-4-carboxylic acid compound, its salt, preparation thereof and preventing agent and remedy for microbism containing the same as active consitutent
DE3006888A1 (de) * 1980-02-23 1981-09-10 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
JPS56118085A (en) * 1980-02-25 1981-09-16 Takeda Chem Ind Ltd 2-methylcephalosporin derivative and its preparation
FR2476647A2 (fr) * 1980-02-26 1981-08-28 Roussel Uclaf Procede de preparation de derives de l'acide 2-(2-amino protege 4-thiazolyl) 2-alkoxyimino acetique isomere syn
US4252802A (en) 1980-03-13 1981-02-24 E. R. Squibb & Sons, Inc. Hydroxamic acid derivatives of 7-[(2-amino-4-thiazolyl)-oximino] cephalosporins
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
US4482551A (en) * 1980-06-26 1984-11-13 Hoffmann-La Roche Inc. Cephalosporin derivatives
US4308267A (en) * 1980-07-03 1981-12-29 Smithkline Corporation 7-[2-Alkoxyimino-2-(amino-thiazole)acetamido]-3-[1-(sulfaminoalkly)tetrazolthiomethyl]cephalosporins
US4443444A (en) * 1980-08-11 1984-04-17 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4399132A (en) * 1980-08-11 1983-08-16 American Cyanamid Company 7-Beta-[alpha-syn-methoxyimino-alpha-(2-aminothiazol-4-yl)-acetamido]-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-3-cephem-4-carboxylic acid and C1 -C6 alkyl derivatives thereof
US4416879A (en) * 1980-09-08 1983-11-22 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
NZ198350A (en) * 1980-09-25 1985-02-28 Toyama Chemical Co Ltd Cephalosporins and intermediates;pharmaceutical compositions
US4507293A (en) * 1980-09-26 1985-03-26 Fujisawa Pharmaceutical Co., Ltd. Antimicrobial cephem compounds
JPS5759894A (en) * 1980-09-30 1982-04-10 Sankyo Co Ltd Cephalosporin for oral administration
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
DK379581A (da) * 1980-10-06 1982-04-07 Hoffmann La Roche Fremgangsmaade til fremstilling af acylderivater
US4367228A (en) 1980-10-29 1983-01-04 Fujisawa Pharmaceutical Co., Ltd. Cephem compound and composition
FR2494279A1 (fr) * 1980-11-20 1982-05-21 Rhone Poulenc Ind Nouvelles oxacephalosporines, leur preparation et les medicaments qui les contiennent
FR2494276A2 (fr) * 1980-11-20 1982-05-21 Rhone Poulenc Ind Nouvelles vinyl-3 cephalosporines, et leur preparation
FR2494275A2 (fr) * 1980-11-20 1982-05-21 Rhone Poulenc Ind Nouveaux derives de vinyl-3 cephalosporines et leur preparation
FR2494280A1 (fr) * 1980-11-20 1982-05-21 Rhone Poulenc Ind Nouveaux derives de la cephalosporine et leur preparation
ES8303422A1 (es) * 1980-12-15 1983-02-01 Fujisawa Pharmaceutical Co Un procedimiento para preparar derivados del acido 7-acilaminocefalosporanico .
JPS6052754B2 (ja) * 1981-01-29 1985-11-21 山之内製薬株式会社 7−アミノ−3−ハロゲノメチル−△↑3−セフェム−4−カルボン酸類およびその製法
EP0058250A3 (de) * 1981-02-17 1983-08-17 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Cephalosporinderivate, deren Herstellung und entsprechende pharmazeutische Präparate
JPS57154175A (en) * 1981-03-16 1982-09-22 Mitsui Toatsu Chem Inc 2-thiazoleamine derivative, its preparation, and drug composition comprising it
JPS57156495A (en) * 1981-03-23 1982-09-27 Kyoto Yakuhin Kogyo Kk Cephalosporin derivative and remedy for microbism used in oral administration
JPS6011917B2 (ja) * 1981-04-09 1985-03-28 山之内製薬株式会社 新規なセファロスポリン化合物
DE3117438A1 (de) * 1981-05-02 1982-11-18 Hoechst Ag, 6000 Frankfurt Cephemderivate und verfahren zu ihrer herstellung
FR2505339A1 (fr) * 1981-05-11 1982-11-12 Rhone Poulenc Sante Nouvelles oxacephalosporines et leur preparation
FR2505338A1 (fr) * 1981-05-11 1982-11-12 Rhone Poulenc Sante Nouvelles oxacephalosporines et leur preparation
DE3118732A1 (de) * 1981-05-12 1982-12-02 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
FR2505840A1 (fr) * 1981-05-13 1982-11-19 Roussel Uclaf Nouveaux produits derives de l'acide 2-amino thiazolyl 2-oxyimino acetamido bicyclo-octene carboxylique, leur procede de preparation et leur application comme medicaments
FR2552089B2 (fr) * 1981-05-13 1985-10-25 Roussel Uclaf Nouveaux produits derives de l'acide 2-amino thiazolyl 2-oxyimino acetamido bicyclo-octene carboxylique, leur procede de preparation et leur application comme medicaments
JPS57193489A (en) * 1981-05-21 1982-11-27 Fujisawa Pharmaceut Co Ltd Syn-isomer of 7-substituted-3-cephem-4-carboxylic acid ester and its preparation
FR2508458A1 (fr) * 1981-06-29 1982-12-31 Sandoz Sa Nouveaux derives de l'acide cephalosporanique, leur preparation et leur application comme medicaments
US4406898A (en) * 1981-09-08 1983-09-27 Eli Lilly And Company Oxazole and oxadiazole cephalosporins
US4396619A (en) * 1981-09-08 1983-08-02 Eli Lilly And Company Cephalosporin betaines
US4577014A (en) * 1981-09-08 1986-03-18 Eli Lilly And Company Thieno and furopyridinium-substituted cephalosporins
US4382932A (en) * 1981-09-08 1983-05-10 Eli Lilly And Company Isoquinolinium substituted cephalosporins
US4396620A (en) * 1981-09-08 1983-08-02 Eli Lilly And Company Cephalosporin quinolinium betaines
IL66726A0 (en) * 1981-09-08 1982-12-31 Lilly Co Eli Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives
JPS5859991A (ja) * 1981-09-14 1983-04-09 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
US4402955A (en) * 1981-10-02 1983-09-06 Eli Lilly And Company Dioximino cephalosporin antibiotics
DE3143537A1 (de) * 1981-11-03 1983-05-11 Hoechst Ag, 6230 Frankfurt Kristalline salze von cefodizim und verfahren zu ihrer herstellung
US4474954A (en) * 1981-12-07 1984-10-02 Bristol-Myers Company Intermediates for cephalosporin derivatives
US4394503A (en) * 1981-12-07 1983-07-19 Bristol-Myers Company Cephalosporin derivatives
US4576938A (en) * 1981-12-08 1986-03-18 Tanabe Seiyaku Co., Ltd. Cephalosporin compound and process for preparing the same
US4501739A (en) * 1982-01-19 1985-02-26 Eli Lilly And Company Thieno and furopyridinium-substituted cephalosporins
US4406899A (en) * 1982-03-04 1983-09-27 Bristol-Myers Company Cephalosporins
JPS58167594A (ja) * 1982-03-26 1983-10-03 Sankyo Co Ltd 経口用セフアロスポリン化合物
US4457929A (en) * 1982-03-29 1984-07-03 Bristol-Myers Company 3-Quaternary ammonium methyl)-substituted cephalosporin derivatives
JPS58210093A (ja) * 1982-05-20 1983-12-07 グラクソ・グル−プ・リミテツド セフアロスポリン抗生物質
ATE30724T1 (de) 1982-06-28 1987-11-15 Bristol Myers Co Cephalosporinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten.
US4500526A (en) * 1982-06-28 1985-02-19 Bristol-Myers Company Cephalosporin derivatives
NL8302309A (nl) * 1982-06-30 1984-01-16 Glaxo Group Ltd Cefalosporinen, preparaten die ze bevatten, en werkwijzen voor de bereiding daarvan.
JPS5913787A (ja) * 1982-06-30 1984-01-24 グラクソ・グル−プ・リミテツド セフアロスポリン化合物
US4616081A (en) * 1982-07-07 1986-10-07 Asahi Kasei Kogyo Kabushiki Kaisha Cephalosporin compounds
JPS59193889A (ja) * 1983-04-18 1984-11-02 Asahi Chem Ind Co Ltd セフアロスポリン系化合物
JPS5910591A (ja) * 1982-07-09 1984-01-20 Meiji Seika Kaisha Ltd 1−オキサデチアセフアロスポリン化合物及びそれを含む抗菌剤
JPS5951291A (ja) * 1982-09-16 1984-03-24 Meiji Seika Kaisha Ltd オキサデチアセフアロスポリン中間体およびその製造法
JPS5946287A (ja) * 1982-07-23 1984-03-15 Meiji Seika Kaisha Ltd 新規1−オキサ−1−デチア−セフアロスポリン誘導体
IL69246A (en) * 1982-08-07 1986-07-31 Tanabe Seiyaku Co 7-((2-aminothiazolyl-2-pyrrolidonyl or(piperidonyl)-oxyimino)acetamido)cephem carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
FR2532936A1 (fr) * 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 2-amino-thiazolyl-4-yl acetique comportant une fonction oxime substituee et leur procede de preparation
US4473577A (en) * 1982-10-22 1984-09-25 Mitsui Toatsu Chemicals, Incorporated 2-Thiazolamine derivatives, process for preparing same, and pharmaceutical compositions comprising same
DK521883A (da) * 1982-11-17 1984-05-18 Toyama Chemical Co Ltd Cephalosporinderivater, fremgangsmaade til fremstilling heraf og fremgangsmaade til fremstilling af mellemprodukter herfor
JPS59106492A (ja) * 1982-11-24 1984-06-20 グラクソ・グル−プ・リミテツド セフアロスポリン抗生物質
JPS59116291A (ja) * 1982-12-06 1984-07-05 Fujisawa Pharmaceut Co Ltd 7−置換−3−セフエム−4−カルボン酸エステルおよびその製法
JPS59104389A (ja) * 1982-12-06 1984-06-16 Shionogi & Co Ltd オキサセファム誘導体
US4608373A (en) * 1982-12-13 1986-08-26 Yamanouchi Pharmaceutical Co., Ltd. Cephem compounds
DE3247614A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4681877A (en) * 1982-12-24 1987-07-21 Kureha Kagaku Kogyo Kabushiki Kaisha Pivaloyloxymethyl 7-β-[2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido]-3-(2-amino-1,3-thiadiazolyl-5-thiomethyl)-3-cepheme-4-carboxylate and pharmaceutical composition containing the same
JPS59118793A (ja) * 1982-12-24 1984-07-09 Kureha Chem Ind Co Ltd セフアロスポリン誘導体及び該誘導体を含有する医薬
JPS59161386A (ja) * 1983-03-01 1984-09-12 Kureha Chem Ind Co Ltd セフアロスポリン誘導体及び該誘導体を含有する医薬
US4499088A (en) * 1983-01-04 1985-02-12 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
JPS59155391A (ja) * 1983-02-22 1984-09-04 Tanabe Seiyaku Co Ltd 新規セファロスポリン誘導体
US4525473A (en) * 1983-03-30 1985-06-25 Bristol-Myers Company Cephalosporins
EP0132501A3 (en) * 1983-03-31 1985-09-18 Ajinomoto Co., Inc. Cephalosporin derivatives, their preparation and pharmaceutical compositions
US4514564A (en) * 1983-04-18 1985-04-30 Eli Lilly And Company 7β-(2'-(1",3",5"-Triazepin-4"-one)-2'-(oxime ether)-acetamido)-3-substituted cephalosporins
JPS59225193A (ja) * 1983-06-02 1984-12-18 Takeda Chem Ind Ltd セフアロスポリンエステル
JPS6041683A (ja) * 1983-07-06 1985-03-05 Asahi Chem Ind Co Ltd 経口用セフアロスボリン誘導体
DE3330605A1 (de) * 1983-08-25 1985-03-14 Hoechst Ag, 6230 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4690921A (en) * 1983-10-11 1987-09-01 Yamanouchi Pharmaceutical Co., Ltd. Cephalosporin compounds and salts thereof
US4692443A (en) * 1983-10-17 1987-09-08 Eli Lilly And Company 3-bicyclicpyridinium-methyl cephalosporins
GB8329030D0 (en) * 1983-10-31 1983-11-30 Fujisawa Pharmaceutical Co Cephem compounds
DE150507T1 (de) * 1983-12-29 1987-02-26 Mochida Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp Cephalosporinverbindungen, verfahren zu ihrer herstellung und pharmazeutishe praeparate.
JPS60142987A (ja) * 1983-12-29 1985-07-29 Mochida Pharmaceut Co Ltd セフアロスポリン誘導体
EP0150609A3 (en) * 1983-12-30 1986-04-23 Glaxo Group Limited Cephalosporin antibiotics
DE3404906A1 (de) * 1984-02-11 1985-08-14 Bayer Ag, 5090 Leverkusen 1-oxadethiacephalosporinderivate sowie verfahren zu ihrer herstellung
DE3405728A1 (de) * 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Verwendung von cephemverbindungen als immunmodulatoren
JPS60174787A (ja) * 1984-02-21 1985-09-09 Kyowa Hakko Kogyo Co Ltd 3位置換カルバセフエム化合物
JPS60178891A (ja) * 1984-02-24 1985-09-12 Kureha Chem Ind Co Ltd セファロスポリン誘導体及び該誘導体を含有する医薬
US4788185A (en) * 1984-04-23 1988-11-29 Takeda Chemical Industries, Ltd. Cephalosporin compounds
JPS60231682A (ja) * 1984-05-02 1985-11-18 Meiji Seika Kaisha Ltd 新規セフアロスポリン系抗菌性化合物及びその製造法
DE3418376A1 (de) * 1984-05-17 1985-11-21 Bayer Ag, 5090 Leverkusen Zwischenprodukte sowie verfahren zur herstellung von zwischenprodukten fuer die synthese von cephalosporinen
FI851934L (fi) * 1984-05-30 1985-12-01 Ici Plc Kefalosporinderivat.
PH22107A (en) * 1984-06-07 1988-06-01 Takeda Chemical Industries Ltd 3-pyrazolo(1,5-a)pyrdinium cephem compounds
JPS6140291A (ja) * 1984-07-31 1986-02-26 Shionogi & Co Ltd ヒドロキシアルキルチオセフアロスポリン
JPS61178991A (ja) * 1984-09-07 1986-08-11 Meiji Seika Kaisha Ltd 新規セフアロスポリン化合物
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
JPH0653739B2 (ja) * 1984-11-15 1994-07-20 協和醗酵工業株式会社 3位置換カルバセフエム化合物
US4868173A (en) * 1984-11-20 1989-09-19 Ici Pharma Cephalosporin derivatives
EP0187456A1 (en) * 1984-11-29 1986-07-16 Ici Pharma Cephalosporin derivatives
JPS61267585A (ja) * 1985-01-16 1986-11-27 Fujisawa Pharmaceut Co Ltd セフアロスポラン酸誘導体もしくはその薬理学的に許容しうる塩
JPS61267584A (ja) * 1985-01-16 1986-11-27 Fujisawa Pharmaceut Co Ltd セフアロスポラン酸誘導体もしくはその薬理学的に許容しうる塩
ATE89826T1 (de) * 1985-03-01 1993-06-15 Takeda Chemical Industries Ltd Antibakterielle verbindungen, ihre herstellung und verwendung.
US4645769A (en) * 1985-03-01 1987-02-24 Merck & Co., Inc. 1-oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same
US4840945A (en) * 1985-04-01 1989-06-20 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
EP0202046B1 (en) 1985-04-30 1991-01-30 Eli Lilly And Company 7-substituted bicyclic pyrazolidinones
GB8519606D0 (en) * 1985-08-05 1985-09-11 Fujisawa Pharmaceutical Co 3 7-d substituted-3-cephem compounds
NO862910L (no) * 1985-08-05 1987-02-06 Fujisawa Pharmaceutical Co Fremgangsmaate for fremstilling av 3,7-disubstituerte-3-cefemforbindelser.
HU196814B (en) * 1985-10-22 1989-01-30 Biogal Gyogyszergyar Process for producing new cepheme-carboxylic acid derivatives
AR243179A1 (es) * 1985-10-29 1993-07-30 Merrell Dow Pharma Procedimiento para preparar nuevas 5-(het)-2,4-dialquil-3h-1,2,4-triazolo-3-tionas
US4670450A (en) * 1985-11-13 1987-06-02 Merrell Dow Pharmaceuticals Inc. Cardiotonic thiazolones
IE862850L (en) * 1985-11-21 1987-05-21 Inst Animal Health Ltd Intermediates for the preparation of beta-lactam antibiotics
GB8626245D0 (en) * 1985-11-27 1986-12-03 Ici Pharma Cephalosporin compounds
DE3542644A1 (de) * 1985-12-03 1987-06-04 Hoechst Ag Verfahren zur herstellung von cefodizim
US4708956A (en) * 1985-12-12 1987-11-24 Kyowa Hakko Kogyo Co., Ltd. 3-position halogenated cephalosporin analogs and pharmaceutical compositions
EP0238060B1 (en) 1986-03-19 1992-01-08 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
DE3750411T2 (de) * 1986-04-14 1995-03-16 Banyu Pharma Co Ltd Cephalosporinderivate, Verfahren zu ihrer Herstellung und antibakterielle Präparate.
JP2503500B2 (ja) * 1986-04-14 1996-06-05 萬有製薬株式会社 新規セフアロスポリン誘導体及びその製造法
US5596102A (en) * 1986-05-23 1997-01-21 Zeneca Limited Biocides
US4822786A (en) * 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
FR2621589B1 (fr) * 1987-10-08 1990-03-02 Sanofi Sa Derives des cephalosporines a pharmacocinetique amelioree, procede pour leur preparation et compositions pharmaceutiques les contenant
US4880798A (en) * 1986-11-25 1989-11-14 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
JPS63132893A (ja) * 1986-11-25 1988-06-04 Mochida Pharmaceut Co Ltd 新規セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
US5262410A (en) * 1986-12-23 1993-11-16 Ici Pharma 3-heterocyclic thiomethyl cephalosporins
EP0272827A3 (en) * 1986-12-23 1990-02-07 ZENECA Pharma S.A. 3-heterocyclicthiomethyl cephalosphorins
JPS63284164A (ja) * 1987-05-15 1988-11-21 Ube Ind Ltd 2−メチル−4−アミノ−5−アミノメチルピリミジン炭酸塩及びその製造方法
EP0304155B1 (en) * 1987-07-23 1995-11-15 ZENECA Pharma S.A. Cephalosporin compounds, process for their preparation and their pharmaceutical compositions
DE3854804T2 (de) * 1987-07-23 1996-06-13 Zeneca Pharma Sa Cephalosporinverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
US4937332A (en) * 1987-12-25 1990-06-26 Taisho Pharmaceutical Co., Ltd. Cephalosporin derivatives
DE3804841A1 (de) * 1988-02-17 1989-08-31 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
JPH01254686A (ja) * 1988-04-05 1989-10-11 Katayama Seiyakushiyo:Kk セフエム化合物およびその製造法
JPH01265093A (ja) * 1988-10-12 1989-10-23 Sankyo Co Ltd 経口用セフアロスポリン化合物
US5391759A (en) * 1988-12-19 1995-02-21 Dowelanco Preparation of 5-acylamino-1,2,4-triazole-3-sulfonamides
DE3910093A1 (de) * 1989-03-29 1990-10-04 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
DE3911322A1 (de) * 1989-04-07 1990-10-11 Hoechst Ag Verfahren zur herstellung von cefodizim-dinatrium
DE3919259A1 (de) * 1989-06-13 1990-12-20 Hoechst Ag Kristalline cephem-saeureadditionssalze und verfahren zu ihrer herstellung
KR930001114B1 (ko) * 1990-07-20 1993-02-18 한국과학기술연구원 세팔로스포린 유도체 및 그의 제조방법
YU48484B (sh) * 1991-05-24 1998-09-18 Hoechst Aktiengesellschaft Kristalne kiselinske adicione soli diastereomerno čistih 1-(2,2-dimetilpropioniloksi)-etilestara 3-cefem-4-karbonske kiseline
DK0531875T3 (da) * 1991-09-07 2004-06-21 Aventis Pharma Gmbh Diastereomer af 3-cephem-4-carboxylsyre-1-(-isopropoxycarbonyloxy)-ethylester og fremgangsmåde til dens fremstilling
AT398764B (de) * 1992-01-28 1995-01-25 Lek Tovarna Farmacevtskih Verfahren zur herstellung von ceftriaxondinatrium-salzhemiheptahydrat
TW212181B (no) * 1992-02-14 1993-09-01 Hoechst Ag
AT399877B (de) * 1992-02-20 1995-08-25 Biochemie Gmbh Neues verfahren zur herstellung von ceftriaxon
ES2117066T3 (es) * 1992-05-21 1998-08-01 Hoechst Ag Procedimiento para la disociacion de esteres profarmacos de cefalosporina para dar acido 7-amino-3-metoximetil-cef-3-em-4-carboxilico.
KR0154901B1 (ko) * 1992-12-26 1998-11-16 성재갑 신규 세팔로스포린계 항생제(v)
GB9423459D0 (en) * 1994-11-21 1995-01-11 Biochemie Gmbh Silylation process
AT402928B (de) * 1994-12-23 1997-09-25 Biochemie Gmbh Neues verfahren zur herstellung von cefotaxim
US7427680B2 (en) * 2001-01-12 2008-09-23 The Regents Of The University Of California Fluorogenic substrates for BETA-lactamase gene expression
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
US6469047B1 (en) * 1999-09-24 2002-10-22 Genentech, Inc. Tyrosine derivatives
US20050234041A1 (en) * 2001-05-16 2005-10-20 Alenka Tomazic Substituted 1-benzazepines and derivatives thereof
US7345081B2 (en) * 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
EP1735000A2 (en) * 2004-04-16 2006-12-27 Genentech, Inc. Method for augmenting b cell depletion
EP1778718B1 (en) * 2004-07-02 2014-10-08 Genentech, Inc. Inhibitors of iap
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
ES2349110T5 (es) * 2004-12-20 2013-11-27 Genentech, Inc. Inhibidores de IAP derivados de pirrolidina
EP2385038A1 (en) * 2005-02-25 2011-11-09 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
RU2451025C2 (ru) * 2005-12-19 2012-05-20 Дженентек, Инк. Ингибиторы iap
US8143426B2 (en) * 2006-07-24 2012-03-27 Tetralogic Pharmaceuticals Corporation IAP inhibitors
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CA2657706A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110224A1 (es) 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
WO2008079735A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
KR20100024923A (ko) * 2007-04-30 2010-03-08 제넨테크, 인크. Iap의 억제제
JP2011509938A (ja) * 2008-01-11 2011-03-31 ジェネンテック, インコーポレイテッド Iapのインヒビター
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック, インコーポレイテッド Iapのインヒビター
EA201170344A1 (ru) * 2008-08-16 2011-08-30 Дженентек, Инк. Азаиндольные ингибиторы iap
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
AR080865A1 (es) 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
AR083953A1 (es) 2010-11-22 2013-04-10 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
CA2934709C (en) 2013-12-30 2022-08-30 Array Biopharma Inc. Serine/threonine kinase inhibitors
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
CA3034705C (en) 2016-08-31 2021-08-03 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
MA49761A (fr) 2017-08-04 2020-06-10 Ardelyx Inc Dérivés d'acide glycyrrhétinique de traitement de l'hyperkaliémie
SG11202108541RA (en) 2019-02-07 2021-09-29 Ardelyx Inc Glycyrrhetinic acid derivatives for use in treating hyperkalemia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36041B1 (en) * 1971-01-29 1976-08-04 Glaxo Lab Ltd Improvements in or relating to antibiotics
GB1389194A (en) * 1971-01-29 1975-04-03 Glaxo Lab Ltd Antibiotics
GB1399086A (en) * 1971-05-14 1975-06-25 Glaxo Lab Ltd Cephalosporin compounds
US4091211A (en) * 1974-05-05 1978-05-23 Hoffmann-La Roche Inc. Cephalosporins
US4020058A (en) * 1974-10-03 1977-04-26 Glaxo Laboratories Limited Improvements in or relating to cephalosporin antibiotics
US4166155A (en) * 1974-10-11 1979-08-28 Gould Inc. Maintenance-free battery
JPS5167524A (ja) * 1974-12-09 1976-06-11 Hitachi Ltd Benchireeshonbarubu
US4298606A (en) * 1974-12-19 1981-11-03 Takeda Chemical Industries, Ltd. Thiazolylacetamido compounds
JPS5760345B2 (no) * 1974-12-19 1982-12-18 Takeda Chemical Industries Ltd
DK154939C (da) * 1974-12-19 1989-06-12 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
FR2361893A2 (fr) * 1976-01-23 1978-03-17 Roussel Uclaf Nouvelles oximes derivees de l'acide 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
FR2346014A1 (fr) * 1976-01-23 1977-10-28 Roussel Uclaf Nouvelles oximes derivees de l'acide 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
DE2760123C2 (de) * 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
SE440655B (sv) * 1976-01-23 1985-08-12 Roussel Uclaf Sett att framstella nya oximderivat av 7-amino-tiazolyl-acetamido-cefalosporansyra
GB1575803A (en) * 1976-03-09 1980-10-01 Fujisawa Pharmaceutical Co 3,7 disubstituted 3 cephem 4 carboxylic acid compounds andprocesses for the preparation thereof
FR2345153A1 (fr) * 1976-03-25 1977-10-21 Roussel Uclaf Nouvelles alcoyloximes derivees de l'acide 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
US4202893A (en) * 1976-03-25 1980-05-13 Roussel Uclaf Alkyloximes of 7-amino-thiazolyl-acetamido-cephalosporanic acids
GB1576625A (en) * 1976-04-12 1980-10-08 Fujisawa Pharmaceutical Co Syn isomer 3,7 disubstituted 3 cephem 4 carboxylic acid compounds and processes for the preparation thereof
US4166115A (en) * 1976-04-12 1979-08-28 Fujisawa Pharmaceutical Co., Ltd. Syn 7-oxoimino substituted derivatives of cephalosporanic acid
DK162391C (da) * 1976-04-12 1992-03-09 Fujisawa Pharmaceutical Co Analogifremgangsmaade til fremstilling af syn-isomerer af 3,7-disubstituerede 3-cephem-4-carboxylsyreforbindelser
JPS597717B2 (ja) * 1976-09-08 1984-02-20 武田薬品工業株式会社 セフアロスポリン誘導体およびその製造法
DE2760484C2 (no) * 1976-04-14 1992-12-03 Takeda Chemical Industries, Ltd., Osaka, Jp
FR2361895A1 (fr) * 1976-08-20 1978-03-17 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-carbamoyloxymethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
JPS6011713B2 (ja) * 1976-09-08 1985-03-27 武田薬品工業株式会社 セフアロスポリン誘導体およびその製造法
FR2381053A1 (fr) * 1977-02-18 1978-09-15 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-thiadiazolyl thiomethyl 7-aminothiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
JPS53103493A (en) * 1977-02-18 1978-09-08 Takeda Chem Ind Ltd Cephalosporin derivatives and process for their preparation
PH17188A (en) * 1977-03-14 1984-06-14 Fujisawa Pharmaceutical Co New cephem and cepham compounds and their pharmaceutical compositions and method of use
FR2384779A1 (fr) * 1977-03-25 1978-10-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-chloro ou 3-methoxy 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
FR2384782A1 (fr) * 1977-03-25 1978-10-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-acetoxymethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
AR229883A1 (es) * 1978-05-26 1983-12-30 Glaxo Group Ltd Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato
US4341775A (en) * 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR0157073B1 (ko) * 1992-10-01 1998-11-16 김태훈 세팔로스포린 유도체 및 그의 제조방법

Also Published As

Publication number Publication date
DE2714880A1 (de) 1978-10-26
BE865632A (fr) 1978-10-03
GR73632B (no) 1984-03-26
IE47211B1 (en) 1984-01-25
SE448378B (sv) 1987-02-16
PT67856B (de) 1979-12-19
US5710146A (en) 1998-01-20
IE780642L (en) 1978-10-02
HK39083A (en) 1983-10-13
JPS5858354B2 (ja) 1983-12-24
FR2485018A1 (fr) 1981-12-24
IL54407A (en) 1985-09-29
FI70221C (fi) 1986-09-15
NZ186842A (en) 1980-11-14
AU528277B2 (en) 1983-04-21
DK143378A (da) 1978-10-03
AT367425B (de) 1982-07-12
AU3464878A (en) 1979-10-04
OA05928A (fr) 1981-06-30
DD137231A5 (de) 1979-08-22
FR2385722A1 (fr) 1978-10-27
FR2485018B1 (no) 1985-04-12
PT67856A (de) 1978-04-01
ES477591A1 (es) 1980-01-01
NO781130L (no) 1978-10-03
GB1604971A (en) 1981-12-16
YU41827B (en) 1988-02-29
ES468475A1 (es) 1979-08-16
US4758556A (en) 1988-07-19
FR2485017A1 (fr) 1981-12-24
JPS549296A (en) 1979-01-24
SE7803660L (sv) 1978-10-03
CS208747B2 (en) 1981-09-15
DK165060C (da) 1993-02-22
FR2485017B1 (no) 1985-04-12
DK165060B (da) 1992-10-05
USRE35754E (en) 1998-03-24
JPS5716887A (en) 1982-01-28
DE2716707A1 (de) 1978-10-19
SE8306994L (sv) 1983-12-16
SE8306994D0 (sv) 1983-12-16
NO160211C (no) 1989-03-22
FR2385722B1 (fr) 1985-09-27
NL7803486A (nl) 1978-10-04
US4278793A (en) 1981-07-14
ATA229078A (de) 1981-11-15
IT1093750B (it) 1985-07-26
CA1259606A (en) 1989-09-19
IT7821901A0 (it) 1978-03-31
JPS6228153B2 (no) 1987-06-18
YU76578A (en) 1983-04-30
IL54407A0 (en) 1978-06-15
CH638810A5 (de) 1983-10-14
FI780966A (fi) 1978-10-03
FI70221B (fi) 1986-02-28
LU79350A1 (de) 1978-11-27

Similar Documents

Publication Publication Date Title
NO160211B (no) Analogifremgangsmaate til fremstilling av nye terapeutisk virksomme cefemderivater.
US2652925A (en) Magnetic treatment device for liquids
US6143171A (en) Magnetic device for treatment of fluids
US3345594A (en) Magnetic device for treating a liquid
US8197684B2 (en) Desalination device using selective membranes and magnetic fields
Faraday Experimental researches in electricity
US5783074A (en) Magnetic fluid conditioner
KR20020021601A (ko) 물의 활성화 방법 및 그 장치
KR910011283A (ko) 원생생물의 성장 억제 방법 및 장치
Bucha Geomagnetic reversals in Quaternary revealed from a palaeomagnetic investigation of sedimentary rocks
US1657574A (en) Method and apparatus for converting electric power
US2518635A (en) Magneto-mechanical movement
GB522294A (en) Improvements in or relating to apparatus for separating magnetic particles from fluids
JPS57185653A (en) Ion-source device
CN205933333U (zh) 永磁磁腔
IL26585A (en) Device for treating a liquid by means of a magnetic field
SU52184A1 (ru) Физический прибор дл демонстрировани унипол рной индукции
Boisgeraud XXXIII. On the action of the Voltaic pile upon the magnetic needle
DE735105C (de) Elektrische Entladungsroehre zur Erzeugung von Elektronen hoher Energie
RU2101232C1 (ru) Способ получения очищенной биологически активной целебной питьевой воды и установка вин-21 "криничка" для его осуществления
DE344210C (de) Vorrichtung zum Abklopfen der Elektroden, insbesondere der Sammelelektroden bei Einrichtungen zur elektrischen Abscheidung von Schwebekoerpern aus Gasen oder Daempfen
CS203766B1 (cs) Zařízeni pro příprava polarizované vody
DE38443C (de) Elektrischer Wasserstandszeiger und Kontroiapparat
SU437118A1 (ru) Электромеханический пол ризованный бленкер
DE393692C (de) Elektrodenanordnung fuer elektrische Gasreinigungsanlagen